CorMedix Inc logo

CRMD

CorMedix Inc

$4

Earnings Summary

Revenue
$0.01Mn
Net Profits
$-7.03Mn
Net Profit Margins
-92118.83%

Highlights

Revenue:

CorMedix Inc’s revenue fell -91.35% since last year same period to $0.01Mn in the Q1 2022. On a quarterly growth basis, CorMedix Inc has generated -86.46% fall in its revenue since last 3-months.

Net Profits:

CorMedix Inc’s net profit jumped 2.53% since last year same period to $-7.03Mn in the Q1 2022. On a quarterly growth basis, CorMedix Inc has generated 9.71% jump in its net profits since last 3-months.

Net Profit Margins:

CorMedix Inc’s net profit margin fell -1026.59% since last year same period to -92118.83% in the Q1 2022. On a quarterly growth basis, CorMedix Inc has generated -566.83% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the CorMedix Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.21
EPS Estimate Current Year
-0.21

Highlights

EPS Estimate Current Quarter:

CorMedix Inc’s earning per share (EPS) estimates for the current quarter stand at -0.21 - a 4.55% jump from last quarter’s estimates.

EPS Estimate Current Year:

CorMedix Inc’s earning per share (EPS) estimates for the current year stand at -0.21.

Key Ratios

Key ratios of the CorMedix Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.18
Return on Assets (ROA)
-0.27
Return on Equity (ROE)
-0.45
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

CorMedix Inc’s earning per share (EPS) jumped 10% since last year same period to -0.18 in the Q1 2022. This indicates that the CorMedix Inc has generated 10% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. CorMedix Inc’s return on assets (ROA) stands at -0.27.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. CorMedix Inc’s return on equity (ROE) stands at -0.45.

Dividend Per Share (DPS):

CorMedix Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-12
-0.22
-0.18
18.18%

Company Information

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product Defencath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. Defencath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop Defencath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. Neutrolin™ is CE Marked and marketed in Europe and other territories as a medical device.

Organisation
CorMedix Inc
Headquarters
Berkeley Heights, New Jersey, US
Employees
35
Industry
Health Technology
CEO
Khoso Baluch